BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36399002)

  • 1.
    El-Hddad S; Sobhy M; Ayoub A; El-Adl K
    J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
    Sharma S; Deep S
    J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
    Purohit P; Dash JJ; Muya JT; Meher BR
    J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
    J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the
    Al-Karmalawy AA; Dahab MA; Metwaly AM; Elhady SS; Elkaeed EB; Eissa IH; Darwish KM
    Front Chem; 2021; 9():661230. PubMed ID: 34017819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
    Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
    J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ibrahim MAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
    Sultan A; Ali R; Ishrat R; Ali S
    J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.